Sotirios Charalampos Diamantoudis1,#,*, Androulla N. Miliotou2,#, Eleftheria Galatou2, Stergiani Telliou3, Konstantinos Sideris4, Nikolaos Grigoriadis1, Ioannis S. Vizirianakis1,2,*
BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216
- 22 October 2025
Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More >
Graphic Abstract